China granted Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) a marketing license for its cobamamide capsules for anemia, according to a Friday filing with the Hong Kong bourse.
Shares closed 1% higher during trading on Monday.
The drug is indicated for conditions such as megaloblastic and nutritional anemia, as well as anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy, the filing said.